berberine has been researched along with Multiple Sclerosis in 2 studies
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Berberine is an alkaloid found in some medicinal plants with anti-inflammatory effects." | 5.91 | Berberine promotes immunological outcomes and decreases neuroinflammation in the experimental model of multiple sclerosis through the expansion of Treg and Th2 cells. ( Haghmorad, D; Sadighimoghaddam, B; Sameni, HR; Soltanmohammadi, A; Tavaf, MJ; Yazdanpanah, E; Yousefi, B; Zargarani, S, 2023) |
| "Berberine (BBR) has shown neuroprotective properties." | 5.46 | The effects of berberine on a murine model of multiple sclerosis and the SPHK1/S1P signaling pathway. ( Chen, R; Jiang, G; Luo, J; Qin, X; Wang, L; Yu, J; Zeng, S, 2017) |
| "Berberine is an alkaloid found in some medicinal plants with anti-inflammatory effects." | 1.91 | Berberine promotes immunological outcomes and decreases neuroinflammation in the experimental model of multiple sclerosis through the expansion of Treg and Th2 cells. ( Haghmorad, D; Sadighimoghaddam, B; Sameni, HR; Soltanmohammadi, A; Tavaf, MJ; Yazdanpanah, E; Yousefi, B; Zargarani, S, 2023) |
| "Berberine (BBR) has shown neuroprotective properties." | 1.46 | The effects of berberine on a murine model of multiple sclerosis and the SPHK1/S1P signaling pathway. ( Chen, R; Jiang, G; Luo, J; Qin, X; Wang, L; Yu, J; Zeng, S, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tavaf, MJ | 1 |
| Soltanmohammadi, A | 1 |
| Zargarani, S | 1 |
| Yazdanpanah, E | 1 |
| Sadighimoghaddam, B | 1 |
| Yousefi, B | 1 |
| Sameni, HR | 1 |
| Haghmorad, D | 1 |
| Luo, J | 1 |
| Chen, R | 1 |
| Zeng, S | 1 |
| Yu, J | 1 |
| Jiang, G | 1 |
| Wang, L | 1 |
| Qin, X | 1 |
2 other studies available for berberine and Multiple Sclerosis
| Article | Year |
|---|---|
Berberine promotes immunological outcomes and decreases neuroinflammation in the experimental model of multiple sclerosis through the expansion of Treg and Th2 cells.
Topics: Animals; Anti-Inflammatory Agents; Berberine; Cytokines; Encephalomyelitis, Autoimmune, Experimental | 2023 |
The effects of berberine on a murine model of multiple sclerosis and the SPHK1/S1P signaling pathway.
Topics: Animals; Berberine; Encephalomyelitis, Autoimmune, Experimental; Female; Lysophospholipids; Mice; Mi | 2017 |